CD38 and Miyoshi myopathy: In contrast, other studies postulated that myeloma stem cells are characterized by a CD38+ CD138+ CD19- CD45- immunophenotype suggesting that stem cell related markers might undergo dynamic changes or differ between MM patients and the experimental model systems (34, 35).